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Lysosomal acid lipase (LAL) is the critical enzyme for the hydrolysis of triglycerides (TGs) and cholesteryl esters
(CEs) in lysosomes. LAL defects cause Wolman disease (WD) and CE storage disease (CESD). An LAL null
(lal5/5) mouse model closely mimics human WD/CESD, with hepatocellular, Kupffer cell and other macrophage,
and adrenal cortical storage of CEs and TGs. The effect on the cellular targeting of high-mannose and complex
oligosaccharide–type oligosaccharide chains was tested with human LAL expressed in Pichia pastoris (phLAL) and
CHO cells (chLAL), respectively. Only chLAL was internalized by cultured ﬁbroblasts, whereas both chLAL and
phLAL were taken up by macrophage mannose receptor (MMR)–positive J774E cells. After intraperitoneal injection
into lal5/5 mice, phLAL and chLAL distributed to macrophages and macrophage-derived cells of various organs.
chLAL was also detected in hepatocytes. Ten injections of either enzyme over 30 d into 2- and 2.5-mo-old lal5/5
mice produced normalization of hepatic color, decreased liver weight (50%–58%), and diminished hepatic cho-
lesterol and TG storage. Lipid accumulations in macrophages were diminished with either enzyme. Only chLAL
cleared lipids in hepatocytes. Mice double homozygous for the LAL and MMR deﬁciences (lal5/5;MMR5/5) showed
phLAL uptake into Kupffer cells and hepatocytes, reversal of macrophage histopathology and lipid storage in all
tissues, and clearance of hepatocytes. These results implicate MMR-independent and mannose 6-phosphate re-
ceptor–independent pathways in phLAL uptake and delivery to lysosomes in vivo. In addition, these studies show
speciﬁc cellular targeting and physiologic effects of differentially oligosaccharide-modiﬁed human LALs mediated
by MMR and that lysosomal targeting of mannose-terminated glycoproteins occurs and storage can be eliminated
effectively without MMR.
Introduction
Lysosomal acid lipase (LAL) hydrolyzes cholesteryl
esters (CEs) and triglycerides (TGs) that are deliv-
ered to the lysosomes by receptor-mediated endocyto-
sis (Goldstein et al. 1975). Mutations in the LAL gene
cause two distinct phenotypes, Wolman disease (WD
[MIM 278000]) and CE storage disease (CESD [MIM
278000]) (Assmann and Seedorf 2001). WD is a rare
infantile-onset disorder, with an incidence of !1/300,000
live births (Meikle et al. 1999). Infants with WD display
hepatosplenomegaly with massive accumulation of mac-
rophages ﬁlled with CEs and TGs in the liver, spleen,
and other organs. In addition, accumulation of CEs in
the zona reticularis of the adrenal gland leads to adrenal
calciﬁcation and insufﬁciency (Assmann and Seedorf
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2001). Patients with WD develop cachexia from mal-
absorption related to the accumulation of engorgedmac-
rophages in the villi of the small intestine (Assmann and
Seedorf 2001). The life span of patients with WD is ∼6
mo. Bone marrow transplantation has had only minimal
therapeutic impact (Krivit et al. 2000). CESD is a later-
onset disorder and has been reported more frequently
than WD. The incidence rate is unknown, but the dis-
order appears to be 2–3 times more common than WD.
Hepatomegaly can be the only clinical manifestation.
This results primarily from the accumulation of mac-
rophages engorged with CEs (Beaudet et al. 1977). Some
patients progress to develop cirrhosis, cholestasis, and
atherosclerosis due to impaired cholesterol and TG ho-
meostasis (Beaudet et al. 1977).
Deletions, insertions, or nonsense mutations in the
LAL locus lead to WD with very low or absent LAL
activity (Grabowski et al. 2003). In comparison, mu-
tations found in patients with CESD have been missense
changes or deletions localized to exon 10. These lead
to small deletions in the C-terminus of the LAL protein
(Grabowski et al. 2003). The milder CESD phenotypes
correlate with the presence of detectible amounts of re-
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sidual enzyme activity (Aslanidis et al. 1996; Redonnet-
Vernhet et al. 1997). Although bone marrow trans-
plantation has been used for WD therapy, therapeutic
efforts for CESD have focused on diminishing the ac-
cumulation of CEs within the liver and spleen by use
of hepatic 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors. Some effects on li-
poprotein metabolism have been observed, but no de-
monstrable phenotypic or outcome effects have been
reported consistently for these agents (Ginsberg et al.
1987).
An LAL null mouse model (lal/) was created by gene
targeting (Du et al. 1998a). The lal/ mice have age-
dependent progressive accumulation of CEs and TGs in
the liver, spleen, small intestine, adrenal gland, and
lymph nodes. The liver, small intestines, and lymph
nodes are engorged with foamy macrophages ﬁlled
with CEs and TGs. By age 6 mo, the lal/ mice also
show complete loss of white and brown adipose tissue
throughout the body (Du et al. 2001a). These mice have
a condition biochemically similar to WD but have sur-
vived into early adulthood (∼8 mo life span).
Enzyme and gene strategies have been tested for ther-
apeutic effects in the lal/ mouse model (Du et al.
2001b, 2002). Human LAL (hLAL) produced in Pichia
pastoris (phLAL) has shown promising results. Perito-
neal administration of phLAL into lal/ mice resulted
in signiﬁcant reductions of hepatomegaly and lipid stor-
age in the liver, spleen, and small intestine. Interestingly,
the reduction of lipid storage in the liver was primarily
in Kupffer cells, whereas the lipid storage in the hepatic
parenchymal cells was mostly unchanged (Du et al.
2001b). Such an effect might be expected from phLAL,
because glycoproteins produced in this yeast have a-
mannosyl–terminated N-linked oligosaccharides (Trim-
ble et al. 2004). Adenoviral gene therapy in lal/ mice
was tested by single intravenous injections of recom-
binant virus containing the hLAL cDNA. The hLALwas
produced primarily in the liver, with secretion into the
bloodstream and uptake by visceral tissues (Du et al.
2001b). Signiﬁcant corrections of lipid storage in the
liver (Kupffer cells and hepatocytes), spleen, and small
intestine were observed by histological and biochemical
analyses (Du et al. 2002).
Here, the cellular targeting and physiologic effects
of phLAL and of hLAL expressed in CHO cell lines
(chLAL) are compared in lal/ mice with and without
intact macrophage mannose receptors (MMRs). Ad-
ministration of phLAL or chLAL to lal/ mice with
intact MMR reduced lipid storage in macrophages.
chLAL also reduced lipid storage in hepatocytes. In mice
with both LAL and MMR disrupted, phLAL produced
improvements in hepatocytes and visceral macrophages.
These results provide insights into the effects of differ-
ential carbohydrate modiﬁcations on cellular targeting
and biological activity, as well as the redistribution of
glycoproteins by mechanisms other than mannose 6-
phosphate (M6P) receptors and MMRs.
Material and Methods
Animals
The mice were provided care in accordance with in-
stitutional guidelines, and all protocols were approved
by the Institutional Animal Care and Use Committee
at the Children’s Hospital Research Foundation. The
lal/ mice originated from mixed genetic backgrounds
of 129Sv, CF-1, and FVB (Du et al. 1998a) and were
backcrossed to a FVB background for 10 generations.
The MMR/ mice were a gift from Dr. Michel Nussen-
zweig, a Howard Hughes Medical Institute Investigator
at The Rockefeller University (Lee et al. 2002). The
lal/;MMR/ double-knockout mice were generated by
crossbreeding of lal/ and MMR/ mice in a C57BL/
6 background. Mice were housed in microisolators, un-
der 12 h/12 h dark/light cycles. Water and food (regular
chow diets) were available ad libitum. The mice were
genotyped by PCR-based screening of tail DNA (Du et
al. 1998a; Lee et al. 2002).
Study Design
Three cohorts of age-matched lal/ mice received 79
mg of phLAL, chLAL, or PBS injections. Two cohorts of
age-matched lal/;MMR/mice received phLAL or PBS
injections. Intraperitoneal (IP) injections were used in
these studies, to mimic the slow infusion of enzyme re-
placement therapy in patients (Barton et al. 1991), rather
than the intravenous boluses used in previous mouse
studies. The injections of phLAL or chLAL were given
to each mouse every 3 d for 30 d, for a total of 10
injections. Enzyme protein was quantiﬁed by immuno-
blotting assays (Du et al. 1998b). The lal/ mice were
harvested 2 d after the ﬁnal injection, and tissues were
processed for histologic, immunohistochemical, and bio-
chemical analyses. phLAL activities were determined us-
ing 4-methylumbelliferyl-oleate (4-MUO) as substrate
(Sheriff et al. 1995). All assays were conducted in du-
plicate. Assays were linear within the time frame used,
and !10% of substrate was cleaved. One U is equal to
1 mM of 4-MUO cleaved per min under standard assay
conditions (Sheriff et al. 1995).
Enzyme Uptake Studies in J774E Macrophages
and Human Fibroblast Cultures
J744E cells expressing MMR (from Dr. Philip Stahl
at Washington University, St. Louis) were used pre-
viously for cellular uptake of phLAL (Du et al. 2001b).
J774E cells were maintained in minimal essential me-
dium with 6-thioguanine (60 mM), and human ﬁbro-
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blasts were maintained in Dulbecco’s minimal essential
medium supplemented with 10% fetal calf serum, pen-
icillin, and streptomycin (at 37C; 5% CO2). For the
uptake studies, cells ( per well) were seeded 1 d52 # 10
before the addition of phLAL or chLAL. The cells were
incubated in medium containing phLAL or chLAL, with
or without M6P, for 24 h and then in fresh media with-
out LAL and were harvested at 48 h. The cells were
washed twice with 1# PBS, were collected with a cell
scraper, and were centrifuged (at 12,000 rpm for 1 min)
at room temperature. The intracellular proteins were ex-
tracted by cell lysis (10 mM NaPO4, 1 mM EDTA, 10
mM dithiothreitol, and 0.5% NP-40; pH 6.8) with son-
ication and were centrifuged (at 12,000 rpm for 10 min)
at 4C. The protein extracts were analyzed by western
blot.
Immunohistochemical Staining and Western Blot
Analyses
Immunohistochemical analyses of parafﬁn-embedded
tissue sections were performed as described elsewhere
(Du et al. 2001b). From the VECTASTAIN ABC kit
(Vector), a second antibody to rabbit anti-hLAL anti-
serum (Du et al. 1996) was used and counterstainedwith
Nuclear Fast Red. Immunoblots were conducted with
anti-hLAL antiserum, as described elsewhere (Du et al.
2001b). The intracellular form of hLAL on western blots
was evaluated by densitometry scanning (Pharmacia
LKB Ultroscan XL).
Tissue Lipid Analyses
Total lipids were extracted from liver, spleen, and
small intestine by the Folch method (Folch et al. 1957;
Du et al. 1998a). TG and cholesterol amounts weremea-
sured by chemical analysis (Rudel and Morris 1973; Du
et al. 2001a).
Histologic Analyses
Light-microscopic examinations of the liver, spleen,
intestine, and adrenal glands were performed. The par-
afﬁn-embedded sections were stained with hematoxylin
and eosin (HE) for light-microscopic analysis. Rep-
resentative sections are presented.
Monosaccharide Composition Analyses
The monosaccharide composition of the oligosac-
charide structures in LAL samples was determined by
acid hydrolysis. Puriﬁed phLAL (80 mg) was incubated
with 250 ml of 2-M triﬂuoroacetic acid at 120C for 2
h. After hydrolysis, the reaction tubes were cooled on
ice, were centrifuged (at 10,000 rpm for 1 min), and
were evaporated to dryness in a vacuum centrifuge. The
released monosaccharides were separated by high-pH
anion exchange chromatography coupled with pulsed
amperometric detection (HPAEC-PAD) on a Dionex
CarboPac PA1 ( mm) column equilibrated and4 # 250
run in 24 mM sodium hydroxide at a ﬂow rate of 1 ml/
min for 20 min. The results were expressed as mole of
sugar per mole of LAL and were determined from linear
curves of authentic, commercially available monosac-
charide standards (E Y Laboratories).
M6P Content
The M6P content of the oligosaccharide structures
in LAL samples were determined by acid hydrolysis.
phLAL (80 mg) was incubated with 6.75 M formic acid
at 100C for 1.5 h. After incubation, samples were
cooled, dried in a vacuum centrifuge, and reconstituted
in distilled water (200 ml). The released M6P was ana-
lyzed by HPAEC-PAD on a Dionex CarboPac PA10
( mm; Dionex) column by use of a 170–400-4 # 250
mM sodium acetate gradient in 100 mM sodium hy-
droxide at a ﬂow rate of 1 ml/min for 15 min. The results
were expressed as mol of M6P per mol of LAL and were
determined from linear curves of authentic, commer-
cially available M6P standards.
Sialic Acid Content
The sialic acid content of the oligosaccharide struc-
tures in LAL samples was determined by mild acid hy-
drolysis. LAL (50 mg) was incubated in 0.5 M formic
acid (at 80C for 60 min). The released sialic acids were
separated by HPAEC-PAD on a Dionex CarboPac PA1
( mm) column by use of a 50–180-mM sodium4 # 250
acetate gradient in 100 mM sodium hydroxide at a ﬂow
rate of 1 ml/min for 20 min. The results were expressed
as mol of sialic acid per mol of LAL andwere determined
from linear curves of authentic, commercially available
sialic acid standards (Toronto Research).
Oligosaccharide Proﬁling
The N-linked oligosaccharides were released from
chLAL and phLAL samples by use of 0.2% (6 U/mg) of
PNGase F and 2-mercaptoethanol (57.2 mM) in sodium
phosphate, pH 7.0, at 37C for 18–20 h. To separate
the deglycosylated protein from the released oligosac-
charides, the digests were centrifuged (at 14,000 rpm for
30 min) using a 10-kDa molecular weight–cutoff regen-
erated cellulose membrane spin-ﬁlters. The ﬁltrates con-
taining the oligosaccharides were dried in a vacuum cen-
trifuge for at least 4 h. The oligosaccharides were re-
constituted in 500 ml of high-performance liquid chro-
matography (HPLC)–grade water and were dialyzed us-
ing a 1-kDa molecular weight–cutoff cellulose acetate
membrane against sodium phosphate, pH 7.0, at 25C
for 18–20 h. The dialysate was dried in a vacuum cen-
trifuge, was reconstituted in 50 ml HPLC-grade water,
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Figure 1 HPLC proﬁles of AA-derivatized phLAL-derived (A) and chLAL-derived (B) oligosaccharides. The proposed structures of
oligosaccharides are listed below each respective graph. LU p Luminescence units.
and was labeled with anthranilic acid (Van Dongen et
al. 1984).
The oligosaccharides were derivatized using the pro-
tocol described by Anumula and Dhume (1998). In brief,
the released oligosaccharides were resuspended in 0.1ml
HPLC-grade water and were labeled with 0.1 ml of la-
beling solution (30 mg anthranilic acid and 25 mg so-
dium cyanoborohydride in 1 ml of 4% sodium acetate
and 2% boric acid in methanol) at 80C for 75 min.
After the labeling, the reactions were quenched with 1
ml of 95% acetonitrile/5% water and were loaded onto
the Oasis HLB cartridges (Waters Corporation). The ex-
cess reagents were removed using 2 # 1-ml washes of
95% acetonitrile/5% water. Derivatized oligosaccha-
rides were eluted using 0.5 ml of 20% acetonitrile/80%
water, were dried, and were resuspended in 125 ml of
20% acetonitrile prior to HPLC analyses.
The AA-labeled oligosaccharides (100 ml sample/
injection) were separated on a Luna NH2 column
( mm; Phenomenex) by use of an HP11004.6 # 250
system equipped with a ﬂuorescent detector (peak ex-
citation wavelength at 230 nm; peak emission wave-
length at 425 nm). The column was equilibrated in 70%
solvent A (2% acetic acid and 1% inhibited tetrahydro-
furan in acetonitrile), and the AA-labeled oligosaccha-
rides were eluted at 50C by use of a gradient consisting
of 30%–95% of solvent B (5% acetic acid, 3% triethyl-
amine, and 1% inhibited tetrahydrofuran in water) at a
ﬂow rate of 1 ml/min for 80 min. The gradient was held
at 95% solvent B for an additional 38 min, to elute the
bisphosphorylated species.
The HPLC chromatographic eluant containing the
AA-derivatized peaks were split after column separation
(∼1:50) and were directly analyzed by electrospray ion-
ization (ESI) mass spectrometry on a ZQ4000mass spec-
trometer (Waters Corporation). The parameters on the
mass spectrometer were capillary voltage at 3.0 kV and
cone voltage at 30 V. The negative-ion ESI mass spec-
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tra were obtained over a mass range of 500–3,750 m/z
at an interval of 5 s per scan. The resulting mass spectra
were obtained by summing at least six scans.
Results
Expression of phLAL and chLAL
phLAL was produced in P. pastoris by use of the yeast
GAPDH promoter and the a factor signal peptide.
chLAL was produced in a CHO cell line by use of the
mouse metallothionine promoter and the hLAL endog-
enous leader sequence. phLAL and chLAL were secreted
into culture media and were puriﬁed to 93%–96% elec-
trophoretic purity as assessed by SDS-PAGE.
Oligosaccharide Proﬁling
The N-linked oligosaccharides from phLAL and
chLAL samples were released using PNGase F, were
ﬂuorescently labeled with anthranilic acid, and were
analyzed by liquid chromatography with online mass
spectrometry. On the basis of mass :charge ratios,
phLAL contained predominantly high-mannose struc-
tures: from Man8GlcNAc2 to Man15GlcNAc2. The most
abundant oligosaccharide structures in phLAL were
Man8–12GlcNAc2 (ﬁg. 1A, retention time ∼28–33
min). In CHO cells, secreted high-mannose N-glycans
(Man9GlcNAc2 and smaller) are observed at low levels,
since most of these structures typically get processed into
Man5GlcNAc2 glycans during passage through the en-
doplasmic reticulum and Golgi compartments. In con-
trast to CHO cells, P. pastoris cells add mannose to this
structure to produce high-mannose N-glycans, with up
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Figure 2 LAL activity in plasma (A) and LAL activity recovery
in liver (B) of lal/ mice that received IP injections of hLAL. Plasma
was collected from phLAL- or chLAL-injected mice at 0, 10, 30, 60,
120, 180, and 240 min after injection. Livers were collected at 240
min after injection. LAL activities in plasma and liver extract were
determined using 4-MUO as the substrate.
Table 1
Monosaccharide Composition and M6P and Sialic Acid Content (per mol of hLAL Protein)
Sample Fucose GlcNac Galactose Mannose GlcNac/Mannose M6P Sialic Acid
phLAL .6 10.0 0 212.0 .05 1.7 .5
chLAL 1.5 11.6 4.1 10.4 1.11 2.2 5.9
to 15 mannose residues. However, in both phLAL and
chLAL, some of the structures get modiﬁed by a
GlcNAc-phosphotransferase, and the GlcNAc residues
are subsequently removed, yielding phosphorylated struc-
tures. Some of the high-mannose structures in phLAL
were either monophosphorylated (Man10–13GlcNAc2,
retention times ∼43–46 min) or bisphosphorylated
(Man7GlcNAc2, retention times ∼100 min).
The glycans from chLAL consisted of a mixture of
complex (sialylated), oligomannose, phosphorylated oli-
gomannose, and hybrid (sialylated and phosphorylated)
structures (ﬁg. 1B). The presence of galactose, sialic acid,
and M6P in the carbohydrate composition assay con-
ﬁrms these glycan structures. The phosphorylated struc-
tures in chLAL were mainly Man6–7GlcNAc2, some of
which still had the additional GlcNAc residue from the
transferase activity. In phLAL and chLAL, composition-
ally identical glycans eluted at different retention times
during the chromatographic separation—for example,
in phLAL, Man9GlcNAc2 eluted at ∼28–29 min, and, in
chLAL, Man7GlcNAc2 eluted at ∼23–26 min. This may
be because of the different isomeric forms of the glycan,
which would have the same mass:charge ratios in this
assay.
Monosaccharide Composition and Sialic Acid and
M6P Content of phLAL and chLAL Oligosaccharides
The oligosaccharide compositions of phLAL and
chLAL were analyzed after acid hydrolysis and sepa-
ration by HPAEC-PAD (table 1). Monosaccharide com-
positional analyses indicated that chLAL and phLAL
contained ∼10 mol of GlcNAc per mol of LAL, sug-
gesting that ﬁve of six potential N-linked oligosaccharide
sites are occupied. The number of experimentally deter-
mined mannose residues (∼10) does not correlate with
the number predicted for ﬁve occupied sites (15 man-
noses would be expected if all were complex oligo-
saccharides). The less-than-expected mannose results
may be because of the fact that the monosaccharide
compositional analysis is highly variable. Also, the
monosaccharide/protein (M/M) results differ from the
theoretical values calculated from the actual identiﬁed
oligosaccharide structures. The chLAL sample had
higher amounts of fucose and galactose, corroborating
the presence of complex-type structures. The phLAL
sample had higher amounts of mannose that correlated
with either high-mannose or pauci-mannosyl structures
in P. pastoris–derived samples. The phLAL samples con-
tained no galactose. Although the monosaccharide re-
sults indicated that phLAL containedminimal sialic acid,
it is well understood that P. pastoris, like plants, does
not possess the necessary enzymes (b1,4 galactosyltrans-
ferases and a2,3 sialyltransferases) to remodel N-linked
glycosylation of oligosaccharide chains (Lerouge et al.
1998; Montesino et al. 1998). The lack of sialylated
glycan structures was conﬁrmed in the oligosaccharide
proﬁling assay (see the “Oligosaccharide Proﬁling” sec-
tion). Both phLAL and chLAL contained phosphoryl-
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Figure 4 Gross pathology of age-matched PBS and phLAL-
treated lal/;MMR/mice. Ventral views (left panel) show the yellow
fatty liver in PBS control lal/;MMR/ mice. In phLAL-treated
lal/;MMR/ mice, the liver had essentially normal color. Gross view
of livers, spleens, kidneys, and mesenteric lymph nodes (right panel,
top to bottom) from PBS and phLAL-treated lal/;MMR/mice. No-
tice that the color of these organs was nearly normal in phLAL-treated
lal/;MMR/ mice.
Figure 3 Tissue cholesterol and TGs in lal/ mice administered
PBS or chLAL. Total cholesterol or total TGs per liver (A) or per
spleen (B) and lipid concentration in intestine (C) was compared be-
tween PBS control mice and phLAL- or chLAL-injected mice ( ).np 6
The P values were from unpaired t tests between PBS and chLAL-
treated samples. * . *** . WT p wild type.P ! .05 P ! .001
ated oligomannosyl structures (1.7 and 2.2 mol M6P
per mol protein, respectively). This amount of M6P is
similar to values reported in the literature for other re-
combinant CHO-derived proteins that are taken up by
the lysosomes via the M6P receptor system (Lee et al.
2003).
Plasma Proﬁles of Injected hLAL
The recovery of hLAL activity in plasma was deter-
mined after IP injection into lal/ mice with intact
MMR and the sampling of blood at 0, 10, 30, 60, 120,
180, and 240 min after injection. The proﬁles (ﬁg. 2A)
of phLAL and chLAL in plasmawere essentially identical
for activities remaining in plasma from 15 to 240 min.
The total LAL activity recovered in the liver at 4 h after
injection was signiﬁcantly greater for chLAL (76.3%)
than for phLAL (23.5%) (ﬁg. 2B).
Phenotypic and Gross Pathologic Changes
To evaluate the metabolic effects of each hLAL,
lal/ mice were injected with PBS, phLAL, or chLAL
(79 mg per dose) every third day over a 30-d period, for
a total of 10 IP injections. phLAL was started at age 2
mo, and chLAL was started at age 2.5 mo. The PBS
control group was staggered between the 2- and 2.5-
mo-old mice. This small age difference does not produce
a signiﬁcantly different degree of disease involvement.
Untreated lal/ mice developed a yellow coloration of
the liver, as well as signiﬁcant hepatosplenomegaly. The
lal/ mice receiving phLAL or chLAL had livers with
more normal color and weight (data not shown). The
livers in age-matched wild-type mice were ∼5% of body
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Figure 6 Anti-hLAL immunohistochemical staining of lal/;MMR/ (A–C) and lal/;MMR/ (D) mouse livers. lal/;MMR/ mice
were given IP injections of PBS (A), phLAL (B), and chLAL (C), and lal/;MMR/ mice were given IP injections of phLAL (D). The amount
of hLAL given to each mouse was 79 mg. Mice were killed 4 h after injection. Liver and spleen were processed for immunohistochemical staining
by use of anti-hLAL antibody. Positive signals were in Kupffer cells of the livers (B–D, arrowheads) and in hepatocytes (C and D, arrows).
Original magniﬁcation, #400.
Figure 7 Comparison of plasma LAL activity between wild-type
and MMR/ mice after a single injected dose of hLAL. Age-matched
wild-type (lower line) and MMR/ (upper line) mice received a single
dose (60 mg phLAL per 25 g body weight) via IP injection. Plasma
was collected from mice at 0, 5, 20, 30, 45, 60, 75, 90, 105, 120,
180, and 240 min after injection. LAL activities in plasma were de-
termined using 4-MUO as the substrate. Plasma volumewas calculated
as 3.5% of body weight. The percentage activity remaining in plasma,
with respect to input LAL activity, was plotted against time.
weight, whereas the livers in the untreated lal/ mice
were ∼14%. In phLAL- and chLAL-injected mice, the
livers were 9.8% (reduced by 30%; ) andPp .0029
7.7% (reduced by 45%; ) of body weight,Pp .0001
respectively.
Biochemical Findings
Tissue cholesterol (free and esteriﬁed) and TGs from
liver, spleen, and small intestine were evaluated in treated
and untreated lal/ mice (ﬁg. 3). Administration of
phLAL to lal/ mice led to 46% reduction in total
hepatic cholesterol ( mg [treated] vs.48.08 2.67
mg [untreated]; ; ) (ﬁg.89.07 2.74 Pp .0003 np 4
3A) and 63% reduction in total splenic cholesterol
( mg vs. mg; ;0.80 0.10 2.19 0.10 Pp .0008 np
) (ﬁg. 3B). Similar decreases in TGs were observed:4
49% reduction in liver ( mg vs.24.84 5.79 48.26
mg; ; ) and 24% reduction in spleen8.97 Pp .025 np 4
( mg vs. mg; ;2.90 1.43 3.80 0.17 Pp .042 np
) (ﬁg. 3A and 3B). Administration of chLAL to lal/4
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Figure 8 Anti-hLAL immunohistochemical staining of lal/;MMR/ (A and C) and lal/;MMR/ (B and D) mouse kidneys. Kidney
sections from PBS-injected mice (A and B) and hLAL-injected mice (C and D) were processed for immunohistochemical staining by use of anti-
hLAL antibody. Only lal/;MMR/ mice had positive uptake of hLAL in kidneys and only in the proximal renal tubular epithelial cells (D).
Original magniﬁcation, #200.
mice resulted in reductions of total hepatic and splenic
cholesterol by 65% ( mg vs.35.19 1.55 99.94
mg; ; ) (ﬁg. 3A) and 67% (0.807.13 P ! .0001 np 6
0.13 mg vs. mg; ; ) (ﬁg.2.45 0.17 Pp .0012 np 6
3B), respectively. The reduction of TGs was 47% in the
liver and 36% in the spleen ( and ,Pp .040 Pp .017
respectively) (ﬁg. 3A and 3B). The cholesterol accu-
mulation in small intestine was unchanged by phLAL
or chLAL administration. However, the TG storage in
small intestine was reduced by 66% and 41% with ad-
ministration of phLAL and chLAL, respectively (ﬁg. 3C).
Lipids in the massively enlarged mesenteric lymph nodes
were not signiﬁcantly changed ( mg vs.3.72 0.17
mg for total cholesterol; vs.4.28 0.7 21.74 5.59
mg for TGs).16.53 2.99
Effects of phLAL Injections into lal/;MMR/ Mice
To evaluate the role of MMR as a major receptor
mediating the therapeutic effects of highly mannosylated
phLAL, double-homozygous knockouts were generated
for lal/ and MMR/. The phenotype of lal/ mice
was not altered in the background of MMR/. Admin-
istration of phLAL (79 mg per mouse, 10 IP injections
given over 30 d) effectively corrected the phenotype in
lal/;MMR/mice. This included the correction of liver
and spleen color and the reappearance of mesenteric fat
(ﬁg. 4). The liver as a percentage of body weight was
reduced in phLAL-treated lal/;MMR/ mice (11.1%
in mice given PBS vs. 8.8% in mice given phLAL;
21%). Even more striking was the reduction in the size
of mesenteric lymph nodes in the phLAL-treated mice
compared with PBS control mice (0.273 g in controlmice
vs. 0.081 g in phLAL-treated mice; 70%)
Histologic Studies
Representative HE-stained liver sections from lal/
mice or lal/ mice with or without MMR and obtained
after PBS, chLAL, or phLAL administration are shown
in ﬁgure 5. Regular phLAL injections led to major re-
ductions in the size and number of lipid-ﬁlled Kupffer
cells (arrowheads in ﬁg. 5B and 5D) in lal/;MMR/
mice. In comparison, the lipid storage in hepatocytes
appeared unaltered (arrows in ﬁg. 5B and 5D). In the
lal/mice treated with chLAL, a reductionwas observed
in the number and size of Kupffer storage cells, and lipid
accumulation was eliminated from hepatocytes (arrow
in ﬁg. 5C). Interestingly, in lal/;MMR/ mice, injec-
tions of phLAL reduced the lipid storage in hepatocytes
(arrows) and Kupffer cells (arrowheads) (compare ﬁg.
5B and 5E). HE staining of other tissues—that is,
spleen and small intestine—indicated that phLAL and
chLAL administration had similar effects in reducing
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Figure 9 Tissues recovery of phLAL. A, LAL activity in tissue
extracts of liver, spleen, and kidney from lal/;MMR/ mice that
received 48 U or 72 U of phLAL and were harvested 4 h after injection.
B, LAL activity recovery in liver, spleen, and kidney as a percentage
of total injected LAL activity in lal/;MMR/ mice.
lipid-storage cells in lal/;MMR/ and lal/;MMR/
mice (ﬁg. 5F–5J and 5K–5O). Similar to the results for
phLAL, chLAL had no effect on lipid storage in lymph
nodes and adrenal glands in lal/;MMR/ mice (data
not shown). Treatment with phLAL in lal/;MMR/
mice had no histological effects on lipid storage in ad-
renal glands or lymph nodes, although there was a re-
duction in lymph node size (ﬁg. 4).
Comparison of Cellular Uptake of phLAL and chLAL
To evaluate the cellular targeting of phLAL and
chLAL in the lal/;MMR/ and lal/;MMR/ mice,
livers were harvested and sectioned at 4 h after injection
(79 mg per mouse) and were processed for immunohis-
tochemical staining with the use of anti-hLAL antibody.
The majority of positive-staining liver cells after injection
of either phLAL or chLAL was in sinusoid-lining cells
(arrowheads, ﬁg. 6B and 6C). Some hepatocyte staining
was also positive in chLAL-injected mice (arrow, ﬁg.
6C). Interestingly, positive staining for phLAL in the
liver of lal/;MMR/ mice was less intense than that
in livers of phLAL-injected lal/;MMR/ mice. How-
ever, unlike injected lal/;MMR/ mice, the lal/;
MMR/mice had positive hLAL signals in both Kupffer
cells and hepatocytes (arrowhead and arrows, respec-
tively, in ﬁg. 6D).
Plasma Pharmacokinetics of hLAL in MMR/ and
MMR/ Mice
Since the deﬁciency ofMMR inmice affects the uptake
of multiple glycoproteins from plasma into tissues and
organs (Lee et al. 2002), the pharmacokinetics of phLAL
uptake was evaluated in MMR/ and MMR/ mice.
After a single dose of phLAL, MMR/ mice showed
rapid uptake into tissues, with ∼1% of injected LAL
activity remaining in plasma after ∼2 h. The MMR/
mice displayed a complex plasma pharmacokinetic pat-
tern, with two major peaks of activity at 15 and 60 min
after injection (ﬁg. 7). The clearance of LAL activity in
plasma was very slow in MMR/ mice, with signiﬁcant
enzyme activities remaining at 4 h after injection. To
evaluate organ uptake of phLAL, immunohistochemical
staining for hLAL was performed in lal/;MMR/ and
lal/;MMR/ mice 4 h after injection. Interestingly, in
addition to liver and spleen, the proximal renal tubular
epithelial cells were strongly positive for LAL staining
in the lal/;MMR/ mouse kidney (ﬁg. 8D). The kid-
neys were negative for hLAL staining after injection
of phLAL into lal/;MMR/ or of PBS into lal/;
MMR/ mice (ﬁg. 8B and 8C). LAL activity in tissue
extracts from lal/;MMR/mice indicated higher LAL-
speciﬁc activity in the kidney than in the liver (ﬁg. 9A),
although the total recovery of phLAL was much less in
the kidney than in the liver because of the size of the
organs (ﬁg. 9B). To further test whether the uptake of
phLAL could be through the M6P receptor, phLAL and
chLAL were incubated with human ﬁbroblasts from an
LAL-deﬁcient patient or MMR-positive J774E cells. Hu-
man ﬁbroblasts were negative for MMR and positive
for M6P receptors. Uptake of chLAL occurred inMMR-
positive J774E cells and M6P receptor–positive human
ﬁbroblasts (ﬁg. 10A). The uptake of chLAL in ﬁbroblasts
can be competed with by M6P (ﬁg. 10B). phLAL was
internalized into J774E cells (Du et al. 2001b), but no
uptake was observed in human ﬁbroblasts (ﬁg. 10A).
The results show that the in vivo uptake of phLAL into
a variety of cells can occur through receptors other than
M6P receptors and MMRs.
Discussion
These data show differential glycosylation of IP-admin-
istered LALs that leads to speciﬁc physiologic and lo-
calization changes at a cellular level. These ﬁndings dem-
onstrate that alternative oligosaccharide processing of
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Figure 10 Cellular uptake of chLAL and phLAL in murine mac-
rophages and human ﬁbroblasts. A, Western blot analysis of cellular
uptake of chLAL and phLAL. Varying amounts of chLAL (unblack-
ened and blackened circles) or phLAL (diamonds) were placed inmedia
surrounding murine macrophage J774E cells (unblackened circles) or
human ﬁbroblasts (blackened circles and diamonds) for 24 h. After
the media was replaced with fresh media without supplemented LAL,
the cells were harvested (at 48 h) and were processed for western blot
analysis. The intracellular form of hLAL was evaluated by densito-
metry scanning. Uptake of chLAL occurred in mannose receptor–pos-
itive J774E macrophages (unblackened circles) and M6P receptor–
positive human ﬁbroblasts from an LAL-deﬁcient patient (blackened
circles). No uptake was observed in human ﬁbroblasts incubated with
phLAL (diamonds). B, Competition of cellular uptake of chLAL in
human ﬁbroblasts by M6P. Various amounts of M6P and 12 mg of
chLAL were coincubated with human ﬁbroblasts for 24 h. Cells were
processed in the same way as described for panel A. The densitometry
signal of intracellular hLAL at 0 mM of M6P was deﬁned as 100%.
Notice that ∼1.5 mM of M6P inhibited ∼50% of chLAL uptake in
ﬁbroblasts.
administered enzymes can lead to clear differential ther-
apeutic effects at a cellular level. The presence of high
mannose oligosaccharides on phLAL leads to prefer-
ential, if not exclusive, uptake by hepatic sinusoidal-
lining cells, including Kupffer cells, and other visceral
macrophages. This produced speciﬁc reductions of CE
and TG storage in these cells of lal/;MMR/ mice. In
comparison, the enzyme produced in CHO cells, chLAL,
led to clearance of CEs and TGs in hepatocytes, Kupffer
cells, other hepatic sinusoidal lining cells, and macro-
phages throughout the bodies of such mice. Importantly,
equal doses of phLAL produced similar degrees of re-
duction in storage cells and lipids in the mice lacking
both lal and MMR (i.e., lal/;MMR/mice). However,
the effects of phLAL in the background of MMR/ pro-
duced signiﬁcantly different clearance effects in the liver
but not in other tissues. In the lal/;MMR/ mice that
received phLAL, the liver showed hepatocellular clear-
ance in addition to signiﬁcant reductions in lipid storage
in Kupffer cells that were comparable to those in chLAL-
treated lal/;MMR/ mice. The clearance of storage
macrophages from the spleen and small intestine by
phLAL was essentially complete in lal/;MMR/ and
lal/;MMR/ mice. Thus, the lack of MMR altered the
physiological effect of the exogenous enzyme-containing
high-mannose residues to include a major effect on he-
patocytes as well as macrophages. This is somewhat sur-
prising in light of the delayed clearance of mannose-
terminated glycoproteins in the MMR/mice (Lee et al.
2002). The low-level presence of M6P receptors on mac-
rophages may account for some uptake and effects of
phLAL, but the completeness of response was greater
than anticipated.
The glycoproteins produced by P. pastoris have either
high-mannose or pauci-mannose structures that con-
tain no galactose and terminal sialic acid residues (ﬁg.
1). In comparison, the CHO cell–produced enzymes,
chLAL and agalsidase b (Lee et al. 2003), have glycans
that contain terminal sialic acid and uncapped galactose
residues that would allow uptake into the lysosomes via
the asialoglycoprotein receptor present on hepatocytes
(Hudgin et al. 1974; Halberg et al. 1987). Indeed, the
CHO cell–produced enzyme agalsidase b has an oli-
gosaccharide content similar to that of chLAL (Lee et
al. 2003). Signiﬁcantly, both agalsidase b and chLAL
were deﬁcient in Man7–10GlcNAc2 structures and did
not contain Man10–15GlcNAc2 structures. Also, phLAL
had little fucosylation, compared with that of chLAL.
The majority of phLAL oligosaccharides contained
Man8–15GlcNAc2 structures and were similar to those
observed in bile salt–stimulated lipase and other pro-
teins produced in P. pastoris (Yamada et al. 1994; Kal-
idas et al. 2001; Hirose et al. 2002; Henriksson et al.
2003). The redistribution of phLAL in theMMR/mice
could be mediated through the M6P receptor but could
also be mediated through other receptors or mecha-
nisms in hepatocytes, such as pinocytosis (Lee et al.
2002). The presence of other mannose receptors with
lower afﬁnity for the structures in phLAL cannot be
excluded.
The poor distribution of mannosylated BSA to liver
and spleen in the MMR/ mice, along with retention
in plasma, supported the MMR as the major controller
of plasma levels of mannosylated glycoproteins (Lee et
al. 2002). MMR was suggested to play a minor role in
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the control of intracellular glycoproteins, particularly
lysosomal enzymes; however, measurements were made
against a high background of various enzymatic activ-
ities, and physiologic roles and speciﬁc cellular targeting
were not assessed. In contrast, in this case, the physi-
ologic effects of phLAL in the lal/;MMR/ back-
ground and the delivery of this enzyme to macrophages
show that more complex mannosyl structures mediate
a different distribution than monomannose-containing
glycoproteins. The detection of phLAL in kidney-prox-
imal tubule epithelial cells may well represent reab-
sorption of ﬁltered hLAL as a result of the prolonged
retention of the enzyme in plasma of these mice.
The physiologic effects of phLAL in the lal/;
MMR/ mice suggest the presence of other uptake
mechanisms that can recognize mannosylated oligosac-
charides for internalization to the hepatic parenchymal
cell lysosome. This was evident by clearance of neutral
lipid storage in hepatocytes by phLAL in these mice.
Importantly, phLAL was taken up selectively by J774E
cells that expressed MMR, whereas no uptake was
noted in J774A cells that did not express MMR (Du et
al. 2001b). Thus, additional receptors in natural mac-
rophages in the liver, spleen, and small intestine could
be present for uptake of the highly mannosylated
phLAL. M6P receptors are present in liver parenchymal
cells and might account for some of the uptake in the
absence of MMR (Geuze et al. 1984). However, the lack
of uptake of phLAL into human WD ﬁbroblasts, which
are positive for M6P receptors and negative for MMR,
makes this unlikely (ﬁg. 10C). Additionally, since the
phLAL contains longer high-mannose oligosaccharides,
the protein could interact withmannose-binding protein
in the plasma, leading to subsequent binding of com-
plement factors that stimulate uptake into macrophages
as well as hepatocytes and hepatic endothelial cells
(Matsuo et al. 1994).
These data demonstrate the physiologic importance
of targeting glycoproteins via speciﬁc uptake mecha-
nisms for a therapeutic effect on lysosomal storage.
These effects are mediated preferentially by MMR, but
additional uptake mediated through the M6P receptor
and/or endocytosis or pinocytosis may be evident when
the MMR is missing or blocked. Such observations may
have direct relevance to the treatment of macrophage-
storage diseases if the observation of downregulation
of MMR in Gaucher storage cells (Boven et al. 2004)
is consistent and is shown for other macrophage-storage
diseases. Such observations would indicate a redirection
to a different population of receptors and/or cells, lead-
ing to alternative uptake or differential uptake into var-
ious cell types, depending on the expression of MMR
at particular stages of the disease process. Clearly, such
pathophysiology requires elucidation for the improve-
ment of therapy for patients.
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